What is the study about?

Acne-ID is looking at the benefits and harms of two different doses of a medication called isotretinoin for the treatment of severe acne in young adults.

Who can take part in the study?

Patients with acne, who have not previously taken oral isotretinoin, between the ages of 12-24 years.  Patients will only be invited to take part in the study once the decision has been taken by the clinician to start isotretinoin.

What is being tested in the study?

Low-dose isotretinoin starting around 0.2-0.3mg per kg per day, likely to be taken over a longer treatment period.

What is this being compared to?

Standard-dose isotretinoin starting around 0.5mg per kg per day, likely to be taken over a shorter treatment period.

What are we trying to find out?

The study will compare the benefits and harms of the two different dose strategies of isotretinoin for people with severe acne (low-dose or standard-dose) to see whether the low dose is as effective at clearing acne as standard-dose.

We will also be looking at side effects and other measures, such as patient reported acne severity, satisfaction with treatment, and mood monitoring, during the trial to see which dose is most effective.

How many patients do we need?

800

Funder

National Institure for Health and Care Research - Health Technology Assessment (NIHR-HTA)